Development
Biogen Inc.
BIIB
$138.60
$3.662.71%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -2.93% | 2.14% | 5.16% | 10.43% | 14.99% |
| Total Other Revenue | -101.81% | -71.25% | -45.76% | -19.68% | 2.38% |
| Total Revenue | -3.32% | -3.57% | -6.23% | -6.61% | -7.36% |
| Cost of Revenue | 9.80% | 5.58% | -1.14% | 11.89% | 59.20% |
| Gross Profit | -9.79% | -8.13% | -8.71% | -13.50% | -23.19% |
| SG&A Expenses | 3.87% | -1.46% | -11.94% | -12.71% | -10.30% |
| Depreciation & Amortization | -2.31% | -15.29% | -20.40% | -71.54% | -68.96% |
| Other Operating Expenses | 3,056.76% | 281.71% | 245.15% | 193.51% | -202.78% |
| Total Operating Expenses | 11.16% | 6.96% | -4.34% | -12.85% | -11.59% |
| Operating Income | -37.64% | -30.00% | -11.14% | 13.68% | 4.50% |
| Income Before Tax | -63.92% | -52.86% | 33.71% | 120.16% | 101.92% |
| Income Tax Expenses | -78.62% | -85.62% | -39.97% | 316.97% | 1,107.63% |
| Earnings from Continuing Operations | -60.78% | -38.87% | 69.25% | 103.08% | 71.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -100.47% | -100.06% | -100.14% | 100.33% | 149.71% |
| Net Income | -61.89% | -48.97% | 29.40% | 115.98% | 95.80% |
| EBIT | -37.64% | -30.00% | -11.14% | 13.68% | 4.50% |
| EBITDA | -32.79% | -27.10% | -11.56% | 10.01% | 4.76% |
| EPS Basic | -61.76% | -48.56% | 31.36% | 120.74% | 101.34% |
| Normalized Basic EPS | -36.84% | -37.87% | -22.71% | 28.97% | 26.56% |
| EPS Diluted | -61.87% | -48.74% | 31.10% | 120.59% | 101.36% |
| Normalized Diluted EPS | -36.89% | -38.01% | -22.85% | 28.96% | 26.56% |
| Average Basic Shares Outstanding | -0.46% | -1.08% | -1.75% | -2.18% | -2.51% |
| Average Diluted Shares Outstanding | -0.45% | -0.92% | -1.56% | -2.09% | -2.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |